Long-Term Bone Remodeling of the Femoral Neck in Osteoporotic Rats Following Local Delivery of Bioactive Drug Molecules
| Author | Affiliation | |
|---|---|---|
Raina, Deepak Bushan | Department of Orthopedics, Lund University, Sweden | |
Qayoom, Irfan | Indian Institute of Technology Kanpur, Kanpur, India | |
Teotia, Arun Kumar | Indian Institute of Technology, Kanpur, India | |
Tanner, K. Elizabeth | Queen Mary University of London, United Kingdom | |
Isaksson, Hanna | ||
| Date |
|---|
2020-10-28 |
no. #3007
ePosters
Background Fragility fractures of the hip are common among the elderly. Zoledronic acid (ZA) is a potent bisphosphonate used clinically with documented positive preventive effect on fragility fractures. In 2018 we published an experimental animal study describing the delivery of a bisphosphonate, ZA alone or in combination with bone morphogenic protein-2 using a calcium sulphate (CaS)/hydroxyapatite (HA) based biomaterial in a critical femoral neck canal defect in osteoporotic rats. We found that local delivery of ZA alone was sufficient to enhance cancellous bone regeneration in the femoral neck canal after a treatment period of 8-weeks but the biomechanical properties of the bone remained unchanged. We hypothesized that a longer follow-up study (6-months) would be necessary to elucidate the long-term bone remodeling effect as well as changes in the biomechanical properties of the bone using this treatment method. Objectives We aimed to evaluate the long-term effects of local ZA and rhBMP-2 delivery on bone remodeling in the femoral neck canal of osteoporotic rats. Study Design & Methods Ovariectomized (OVX) female Sprague-Dawley rats were used after a 16-week waiting period post-OVX (average weight: 420±20, age at operation: 24-weeks). A 1-mm burr was used to drill a hole in the femoral neck canal of the rats and the defect was treated as follows: G1) Empty (n=8), G2) CaS/HA biomaterial (n=8), G3) CaS/HA biomaterial + Systemic ZA (s.c injection, 2-weeks post implantation (0.1 mg/kg)) (n=11), G4) CaS/HA+ Local ZA (10 µg) (n=11) and G5) CaS/HA+ Local ZA (10 µg)+rhBMP-2 (5 µg) (n=9). G3 was added to this study in order to compare standard of care systemic ZA delivery with local ZA delivery in this model. Finally, to establish that the CaS/HA biomaterial is an optimal carrier for local ZA delivery, we used 14C-ZA to study the bioavailability of ZA during the entire course of bone regeneration and compare it [...].